80 related articles for article (PubMed ID: 26471970)
1. Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Ferrari SM; La Motta C; Sartini S; Baldini E; Materazzi G; Politti U; Ruffilli I; Ulisse S; Miccoli P; Antonelli A; Fallahi P
Mini Rev Med Chem; 2016; 16(2):86-93. PubMed ID: 26471970
[TBL] [Abstract][Full Text] [Related]
2. N- and s-substituted Pyrazolopyrimidines: A promising new class of potent c-Src kinase inhibitors with prominent antitumor activity.
Awaji AA; Zaloa WAZE; Seleem MA; Alswah M; Elsebaei MM; Bayoumi AH; El-Morsy AM; Alfaifi MY; Shati AA; Elbehairi SEI; Almaghrabi M; Aljohani AKB; Ahmed HEA
Bioorg Chem; 2024 Apr; 145():107228. PubMed ID: 38422592
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant.
Li X; Su J; Yang Y; Lian W; Deng Z; Yang Z; Chen G; Zhang B; Dong C; Liu X; Li L; Wang Z; Hu Z; Xu Q; Deng X
Eur J Med Chem; 2020 Dec; 207():112755. PubMed ID: 32882611
[TBL] [Abstract][Full Text] [Related]
4. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.
Roskoski R
Pharmacol Res; 2021 Mar; 165():105463. PubMed ID: 33513356
[TBL] [Abstract][Full Text] [Related]
5. An assessment study of known pyrazolopyrimidines: Chemical methodology and cellular activity.
Rao RN; Chanda K
Bioorg Chem; 2020 Jun; 99():103801. PubMed ID: 32278206
[TBL] [Abstract][Full Text] [Related]
6. Molecular Modelling Studies on Pyrazole Derivatives for the Design of Potent Rearranged during Transfection Kinase Inhibitors.
Bhujbal SP; Keretsu S; Cho SJ
Molecules; 2021 Jan; 26(3):. PubMed ID: 33525725
[TBL] [Abstract][Full Text] [Related]
7. Recent developments of RET protein kinase inhibitors with diverse scaffolds as hinge binders.
Jia CC; Chen W; Feng ZL; Liu ZP
Future Med Chem; 2021 Jan; 13(1):45-62. PubMed ID: 33242992
[No Abstract] [Full Text] [Related]
8. Pyrazolopyrimidines as anticancer agents: A review on structural and target-based approaches.
Asati V; Anant A; Patel P; Kaur K; Gupta GD
Eur J Med Chem; 2021 Dec; 225():113781. PubMed ID: 34438126
[TBL] [Abstract][Full Text] [Related]
9. Application and SARs of Pyrazolo[1,5-a]pyrimidine as Antitumor Agents Scaffold.
Zhang Y; Wen D; Shen J; Tian L; Zhu Y; Zhang J; Zhao L; Ding S; Liu J; Chen Y
Curr Top Med Chem; 2023; 23(12):1043-1064. PubMed ID: 36852801
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Antibacterial Evaluation of New Pyrazolo[3,4-
Greco C; Catania R; Balacco DL; Taresco V; Musumeci F; Alexander C; Huett A; Schenone S
Molecules; 2020 Nov; 25(22):. PubMed ID: 33207806
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents.
Guo T; Ma S
ChemMedChem; 2021 Feb; 16(4):600-620. PubMed ID: 33179854
[TBL] [Abstract][Full Text] [Related]
12. Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism.
Basolo A; Matrone A; Elisei R; Santini F
Semin Cancer Biol; 2022 Feb; 79():197-202. PubMed ID: 33476722
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer.
Wu X; Liu Z; Gan C; Wei W; Zhang Q; Liu H; Que H; Su X; Yue L; He H; Ouyang L; Ye T
Bioorg Chem; 2022 Oct; 127():105965. PubMed ID: 35759882
[TBL] [Abstract][Full Text] [Related]
14. The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies.
Nitulescu GM; Stancov G; Seremet OC; Nitulescu G; Mihai DP; Duta-Bratu CG; Barbuceanu SF; Olaru OT
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513232
[TBL] [Abstract][Full Text] [Related]
15. Explanatory review on pyrimidine/fused pyrimidine derivatives as anticancer agents targeting Src kinase.
Teli G; Pal R; Maji L; Purawarga Matada GS; Sengupta S
J Biomol Struct Dyn; 2024; 42(3):1582-1614. PubMed ID: 37144746
[TBL] [Abstract][Full Text] [Related]
16. Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis.
Janetka JW; Hopper AT; Yang Z; Barks J; Dhason MS; Wang Q; Sibley LD
J Med Chem; 2020 Jun; 63(11):6144-6163. PubMed ID: 32420739
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One Decade (2011-2020): Current Status and Future Prospects.
El-Gamal MI; Zaraei SO; Madkour MM; Anbar HS
Molecules; 2022 Jan; 27(1):. PubMed ID: 35011562
[TBL] [Abstract][Full Text] [Related]
18. Role of Tyrosine Kinases and their Inhibitors in Cancer Therapy: A Comprehensive Review.
Kumar V; Kaur N; Sahu S; Sharma V; Kumar D; Sharma A; Wadhwa P
Curr Med Chem; 2023; 30(13):1464-1481. PubMed ID: 35894454
[TBL] [Abstract][Full Text] [Related]
19. GO Nanosheets: Promising Nano Carrier for the S29, 1-(2-Chloro-2-(4-chlorophenyl-ethyl)-
Mardente S; Aventaggiato M; Mari E; Francioso A; Tafani M; Mosca L; Zicari A; Malyshev I; Kuznetsova L; Valentini F
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899395
[TBL] [Abstract][Full Text] [Related]
20. Medicinal Chemistry of Pyrazolopyrimidine Scaffolds Substituted with Different Heterocyclic Nuclei.
Elgemeie GH; Azzam RA; Zaghary WA; Khedr MA; Elsherif GE
Curr Pharm Des; 2022; 28(41):3374-3403. PubMed ID: 36330628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
